- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 4.17 EX-4.17
- 4.26 EX-4.26
- 4.33 EX-4.33
- 4.34 EX-4.34
- 4.35 EX-4.35
- 4.36 EX-4.36
- 4.37 EX-4.37
- 4.38 EX-4.38
- 4.39 EX-4.39
- 4.40 EX-4.40
- 4.44 EX-4.44
- 4.45 EX-4.45
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15.1 EX-15.1
- 15.2 EX-15.2
- 16.1 EX-16.1
- Download Excel data file
- View Excel data file
Exhibit 13.1
Certification by the Chief Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the annual report of Mereo BioPharma Group plc (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Denise Scots-Knight, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 31, 2022
By: | /s/ Denise Scots-Knight, Ph.D. | |
Name: | Denise Scots-Knight, Ph.D. | |
Title: | Chief Executive Officer |